Head-to-head · free
Thermo Fisher Scientific vs U.S. Physical Therapy
TMO vs USPH — return on capital, cash generation, margins and balance sheet side by side.
TMO
6 / 8
measures where TMO leads
USPH
2 / 8
measures where USPH leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | TMO · FY2025 | USPH · FY2025 |
|---|---|---|
| Revenue | $44.6B | $781.0M |
| Net income | $6.7B | $39.6M |
| Revenue growth (yearly, multi-year) | 3.2% | 12.1% |
| Free cash flow | $6.3B | — |
| Free cash flow margin | 14.1% | — |
| Net cash / (debt) | — | — |
| ROIC | 8.3% | 6.0% |
| Return on equity | 13.0% | 3.1% |
| Gross margin | 40.9% | 19.2% |
| Operating margin | 18.2% | 10.3% |
| Net debt / EBITDA | 2.81x | 1.16x |
Figures are as reported by each company; latest fiscal year shown.
Where Thermo Fisher Scientific's cash went (FY2025)
- Capital spending
- $1.5B
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where U.S. Physical Therapy's cash went (FY2025)
- Capital spending
- —
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free